Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without

There is a common misconception in the clinical research community about what the FDA's Real-Time Clinical Trials (RTCT) initiative actually proposes. Many assume it means regulators will be watching live trial data like a surveillance feed—a continuous, unfiltered stream of raw clinical information. This interpretation is inaccurate, and the distinction matters considerably.

What the FDA is proposing through RTCT is something far more precise: predefined, clinically meaningful signals transmitted in near real-time, giving regulators continuous visibility into emerging trial risk while the study is still running—not after database lock. The speed of data transmission is not the objective. The quality and interpretability of the signal is.¹

This distinction changes the entire conversation. Because the quality of what regulators will see depends entirely on how well sponsors have designed their upstream signal architecture—their key risk indicators (KRIs), quality tolerance limits (QTLs), escalation pathways, and contextual interpretation logic. In other words: poor KRI design in risk-based quality management (RBQM) leads directly to poor signal intelligence in RTCT.¹⁰

RBQM as infrastructure, not methodology

Risk-based quality management has long been characterized as a monitoring methodology—a smarter, more targeted approach to site oversight that replaces 100% source data verification with risk-stratified, centralized review. While accurate, this framing undersells RBQM's role in the emerging regulatory landscape.^2,8

RBQM is not simply a monitoring strategy. It is the foundational infrastructure upon which real-time regulatory visibility must be built. The FDA's RTCT proposal does not create a new layer of oversight—it elevates an existing one. The signal intelligence that centralized monitoring professionals generate daily is precisely the output that RTCT requires at a regulatory level.^3,4

A three-layer model for understanding RTCT readiness

To understand the infrastructural relationship between RBQM and RTCT, it is useful to conceptualize clinical trial operations across three distinct layers:

Layer 1: Operational execution

This is the visible surface of trial conduct. Sites collect data. Queries are raised and resolved. Monitoring activities are scheduled and executed. Investigational products are accounted for. Informed consent is documented. This layer is operationally intensive and highly regulated, but it does not, by itself, generate the kind of interpretable risk signals that support proactive decision-making.

Layer 2: Signal intelligence

This is where centralized monitoring operates. Layer 2 converts raw operational activity into meaningful clinical risk signals through KRI tracking, QTL analysis, statistical surveillance, outlier detection, trend analysis, and root cause analysis (RCA). It is here that a data point becomes a pattern, and a pattern becomes an actionable risk insight.⁵

Examples of Layer 2 signal outputs include:

• A single site contributing a disproportionate percentage of total protocol deviations across a study
• An adverse event underreporting trend quietly emerging weeks before formal escalation thresholds are breached
• Enrollment behavior patterns that predict future protocol risk before it manifests in compliance metrics

Layer 3: Regulatory integration

This is where RTCT resides. Layer 3 involves regulators observing emerging risk signals during active study conduct rather than reviewing aggregate findings post-database lock. The critical insight is that Layer 3 is entirely dependent on the maturity of Layer 2. You cannot build effective regulatory integration on a weak signal intelligence foundation. Most organizations are still developing Layer 2 capability. Those attempting to implement RTCT without first strengthening Layer 2 risk creating a system that transmits noise rather than intelligence to regulators.

The signal noise problem in real-time environments

Perhaps the most underappreciated challenge in RTCT implementation is this: real-time environments do not simply deliver more data. They amplify noise.

Centralized monitoring professionals already encounter this challenge in routine practice. A KRI breach that appears significant in a monthly review dashboard may reflect transient operational variability rather than true quality deterioration. The metric moves—but the underlying driver is not site non-compliance. It may be delayed site onboarding, staggered data entry cycles, regional workflow differences, or EDC configuration behavior.

A concrete example from operational practice: a site showed a marked spike in query rate during the screening period, which initially presented as a potential data quality concern. Following RCA and trend contextualization, the elevated query rate was attributable to system-generated queries triggered automatically by EDC configuration logic during screening data entry—not to actual site non-compliance. The dashboard showed the what. The RCA revealed the why.

In a real-time regulatory environment, this distinction becomes critical. Without robust contextual interpretation mechanisms, a spurious KRI breach could trigger regulatory scrutiny of a high-performing site. The consequence is not merely operational inefficiency—it is misallocated regulatory attention and potential disruption to trial conduct.⁶

Emerging challenges in RTCT implementation

Four challenges that are already present in centralized monitoring practice will be amplified in RTCT environments:

• Signal overload: The volume of KRI data across global trials already creates prioritization challenges. Real-time transmission to regulators compounds this problem unless signal filtering and triage logic are established upstream.
• AI explainability: As AI-assisted risk detection becomes integrated into RBQM platforms, the ability to explain why a signal was generated becomes a regulatory requirement, not merely a technical preference. Black-box algorithms are incompatible with a transparency-focused regulatory framework.⁷
• Site variability: Multi-regional trials introduce systemic operational variability that can produce KRI patterns that appear anomalous in isolation but are entirely expected in context. RTCT frameworks must account for regional norms in signal interpretation.
• Governance over clinical meaningfulness: There is currently no standardized definition of what constitutes a "clinically meaningful signal" for RTCT transmission purposes. This governance gap must be addressed before RTCT can function as a reliable regulatory tool.¹¹

Implications for the clinical research workforce

The professionals who will shape RTCT implementation are not, in all likelihood, a new category of regulatory specialist. They are the centralized monitoring professionals already trained to interpret systems, identify patterns, and generate contextually grounded risk assessments from complex multi-site data environments.

The analytical competencies developed in RBQM—KRI design, QTL calibration, signal triage, RCA, cross-functional risk communication—are precisely the competencies that RTCT requires. This has workforce implications for how the industry recruits, trains, and positions centralized monitoring roles in the organizational hierarchy.

It also has implications for how sponsors invest in their signal infrastructure. Organizations that have treated centralized monitoring as a cost-reduction exercise—rather than as a strategic analytical function—will face significant structural limitations as RTCT timelines approach.

Conclusion

Real-Time Continuous Trials represent a significant evolution in the regulatory framework for clinical research. But RTCT is not, fundamentally, a new idea. It is the logical destination of a trajectory that began with ICH E6(R2)'s endorsement of risk-based approaches and accelerated through the operational maturation of centralized monitoring during and after the COVID-19 pandemic.⁹

The critical recognition for the industry is this: RTCT does not function independently of the RBQM infrastructure that precedes it. The three layers—Operational Execution, Signal Intelligence, and Regulatory Integration—are sequential and dependent. Regulatory integration is only as reliable as the signal intelligence that feeds it. And signal intelligence is only as meaningful as the operational discipline that generates it.

For organizations preparing for RTCT, the most important investment is not in new technology or regulatory engagement strategies. It is in the maturation of Layer 2—the signal intelligence capabilities that already exist, in varying stages of development, inside centralized monitoring functions across the industry.

RBQM works best when data triggers thinking, not just action. RTCT will work best when that thinking has already been institutionalized.

Disclosures

Conflict of Interest: The author declares no conflicts of interest.

Funding: This work received no external funding.

Acknowledgements: The author acknowledges the broader centralized monitoring and RBQM practitioner community whose shared professional discourse informed the perspectives presented in this article.

About the author

Mohamed Natheem is a centralized monitoring assistant at IQVIA, Bangalore, where he oversees 46+ clinical trial sites across 10 countries for global Phase II studies. He holds a B.Tech in Pharmaceutical Technology and a PG Diploma in Clinical Research. He has generated over 300 risk signals and 400 site risk assessment reports in support of RBQM-driven trial oversight. He is a recipient of the IQVIA Ovation Award for Best Beginner. His previous publications include work on Decentralized Clinical Trials and the comparative evolution of ICH E6(R3).

References

1. U.S. Food and Drug Administration. Real-Time Continuous Trials: Concept Paper. Silver Spring, MD: FDA; 2023. Available at: https://www.fda.gov/science-research/fda-science-forum/real-time-continuous-trials
2. International Council for Harmonisation. ICH Harmonised Guideline E6(R2): Good Clinical Practice. Geneva: ICH; 2016.
3. TransCelerate BioPharma. Risk-Based Monitoring Methodology: Position Paper. Philadelphia, PA: TransCelerate; 2013. Available at: https://transceleratebiopharmainc.com
4. U.S. Food and Drug Administration. A Risk-Based Approach to Monitoring of Clinical Investigations: Questions and Answers — Guidance for Industry. Silver Spring, MD: FDA; 2023.
5. Venet D, Doffagne E, Burzykowski T, et al. A statistical approach to central monitoring of data quality in clinical trials. Clin Trials. 2012;9(6):705–713. doi:10.1177/1740774512447898
6. Morrison BW, Cochran CJ, White JG, et al. Monitoring the quality of conduct of clinical trials: a survey of current practices. Clin Trials. 2011;8(3):342–349. doi:10.1177/1740774511402703
7. Hallgreen CE, Bretz F, Hampson LV, et al. Interaction between clinical trial stakeholders and regulators in the development of estimands and statistical analysis plans. Pharm Stat. 2021;20(5):998–1015. doi:10.1002/pst.2131
8. International Council for Harmonisation. ICH Harmonised Guideline E6(R3): Good Clinical Practice. Geneva: ICH; 2023.
9. Natheem M. Decentralized Clinical Trials: Operational Considerations and the Evolution of Remote Monitoring. [Previously published work by author]; 2024.
10. U.S. Food and Drug Administration. Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring: Guidance for Industry. Silver Spring, MD: FDA; 2013.
11. European Medicines Agency. Guideline on Risk-Based Approaches in Clinical Trials. EMA/269011/2013. Amsterdam: EMA; 2013.